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8Abstract
Background: - Multi Drug Resistance Tuberculosis is a growing public health problem in
all over the world. The treatment of Multi drug resistance tuberculosis is very important
because of the risk of transmitting virtually untreatable drug resistant disease. When
patients are not timely and appropriately assessed and managed for adverse effects of
second line drugs the consequence will be life treating.
Objective: - To determine Magnitude of adverse effect in Multi drug resistance
tuberculosis treatment and associated factors at St Peters TB specialized hospital and
Gondar university hospital, Ethiopia.
Method: - Institution based retrospective cross sectional study was conducted from April
1-20, 2014. A total of 540 patients were enrolled in this study and data was collected using
pre tested structured check list by trained health professional. The collected data was
reviewed and checked for completeness before data entry, coded and entered to Epi-info
version 3.5.1 and was exported to SPSS version 20 for descriptive. Bivariate and
multivariate logistic regression model were used to identify the associated factors of
adverse effects. The degree of association between independent and dependent variables
was assessed by using odds ratio with its 95% confidence interval.
Results: -. A total of 486 (90%) patients had at least one adverse effect while on treatment
of Multi drug resistance tuberculosis. The most common adverse effects are severe
gastritis (72.96%) followed by Arthralgia (limit mobility) (40.74%) and psychiatric disorder
(30.56%). Body mass index less than 16.5kg/m2 [AOR: 2.83, 95% CI: (1.57-5.08)] and
HIV positive patients [AOR: 2.34, 95% CI: (1.14-4.79)] are significantly associated with
Multi drug resistance tuberculosis treatment adverse effect.
Conclusion: - The prevalence of common adverse effect on Multi drug resistance
tuberculosis treatment was high. Nutritional and HIV status are the associated factors for
drug adverse effect. Therefore, especial emphasis for malnourished and HIV co infected
patients should be given while they are taking anti Multi drug resistance tuberculosis
treatment at treatment initiating centers.
Key words: Multi drug resistance tuberculosis, adverse effect, second line drugs,
magnitude
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1.1 Statement of problem
Multi drug resistance tuberculosis is a growing public health problem in all over the world.
The treatment of MDR TB is very important because of the risk of transmitting when left
untreated (1). One of the challenges facing patients treated with second-line drugs (SLD)
is the toxic nature of these drugs (2).
WHO global TB report estimated that globally in 2012, data from drug resistance surveys
and continuous surveillance among notified TB cases suggest that 3.6% of newly
diagnosed TB cases and 20% of those previously treated for TB had MDR-TB. The high-
est levels of MDR-TB are found in Eastern Europe and central Asia, where in some
countries more than 20% of new TB cases and more than 50% of those previously treated
for TB have MDR-TB (3). About 60% of these cases occurred in Brazil, China, India, the
Russian Federation and South Africa alone (“BRICS”) countries (4).
Ethiopia is one of among 27 high MDR-TB burden countries that carry 87% of the total
global burden and one of the four countries in Africa. A survey done 2011-2013 on drug
resistance tuberculosis result showed that, 1.6% of new cases and 11.8% of retreatment
cases in Ethiopia were resistance to isoniazid and rifampicin, (MDR-TB) (5).
MDR TB treatment is both toxic and expensive. The drugs have many side effects which
cause to interrupt the therapy. Previous studies have shown that patients with drug
resistant tuberculosis have lower response rates than those with drug susceptible isolates
(6). Side-effects such as drug induced hepatitis, dyspepsia; exanthema and arthralgia
were responsible for termination of therapy in up to 23% of patients during the intensive
phase (7). Medication side-effects were also found to be significantly associated with
defaulting (8).
Adverse effects of the drugs increase the bad outcomes of treatment like defaulters.  A
study carried out in Kyrgyzstan prisons, in 2007 reported that medication side-effects were
among the most common reasons for patient non-attendance at DOTS clinics. The side-
effects profile of TB chemotherapy is magnified in patients with concurrent HIV treatment
and/or prior history of hepatitis (9), Those patients treated with second-line drugs for
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multidrug-resistant TB, during which as many as 86% of patents may develop medication
side-effects (10,11).
When patients are not timely and appropriately assessed and managed for adverse effect
of second line drugs adverse effect is life treating. According to study on patients with HIV
co infection in Mumbai hospital show that among  81 patients eleven patients were
hospitalized for adverse effect during the study period. The main reasons for
hospitalization were life-threatening events (severe renal impairment, hypokalemia),
seizures or severe psychiatric symptoms. Hospitalization was generally short (less than a
week) and only two of the eleven patients had to be hospitalized more than once; both of
them for hypokalemia. Looking at final treatment outcomes, adverse effect might have
contributed to defaulting of two patients and death of four patients (12).
Recognizing the magnitude of adverse effect of MDR-TB treatment helps to give emphasis
for treatment initiating centers on evaluation and monitoring of adverse effect of patients
while treating patients on MDR-TB and helps Ministry Of Health and program designers to
fulfill laboratory set ups and to plan for ancillary medications for treating the adverse
effects while establishing treatment initiating centers.
Identifying associated factors for the adverse effect of MDR-TB treatment helps treatment
initiating centers and treatment follow up centers to give special attention for patients with
the factors and helps to increase the treatment outcome of MDR-TB treatment.
However, there is no research done in Ethiopia previously that show magnitude and
factors associated with adverse effect of MDR-TB treatment .Therefore, this study was
designed to determine the magnitude of adverse effect of MDR-TB treatment and
associated factors in Ethiopia.
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1.3 Literature review
Timely and intensive monitoring and management of adverse effects caused by second-line
drugs are essential components of MDR-TB control programmes. Treatment of MDR-TB is
difficult because of second line drugs have high side effect rates in MDR-TB treatment that
leads compromised success rates. Poor management of adverse effects increases the risk of
default or irregular adherence to treatment, and may result in death or permanent morbidity
(4).
1.3.1 Magnitude of adverse effects of MDR-TB treatment
Adverse effect of MDR- TB treatment are high in magnitude and some of the adverse effect
are severe and life treating. According to a study conducted at Nepal in 2009 with
retrospective cohort adverse effect of second line drugs show that from a total 70 MDR- TB
patients on second line drugs 74.3% experienced adverse effects of drugs ranging from mild
to severe. From those patients around 9.9% of patients were having serious adverse effects
requiring hospitalization which include severe adverse arthralgia, hypokalemia, suicidal
ideation and hepatitis (13).
A study with retrospective review in 2013 at Peru from 60 patients showed that from mild to
severe adverse effects in 10% patients (14).
According to a prospective study conducted at Mumbai in 2012 showed that overall, 71%,
63% and 40% of patients experienced one or more mild, moderate or severe AE respectively.
AE were most commonly attributed to cycloserine, ethionamide and p-aminosalicylic acid.
There were 151 episodes of AE during the study period, 29 of them severe. Life-threatening
events were rare: only one patient experienced severe Hypokalemia eight weeks after
treatment initiation and two patients (3.0%) experienced severe renal impairment, which was
diagnosed after 16 and 24 weeks of therapy respectively (14).
A retrospective cohort study carried out at Egypt in 2009 show that the prevalence of adverse
effect on MDR-TB patient’s show that gastritis is the leading adverse effect that accounts
88.3% of patients, peripheral neuritis is the second leading adverse effect that accounts for
76.7%, hypothyroidism is the third common adverse effect with 44.4% of patients develops
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hypothyroidism. Hypokalemia also account around 23.3 % of from those develop adverse
effect and CNS complication is one adverse effect from treatment of MDR-TB in this study
accounts 16.1% of cases. Gout arthritis contributes for 14.4% of adverse effect developed,
13.3% of patients develop ototoxicity and hepatitis also contributes for 8.3% of patients (15).
1.3.2 Associated factors of Adverse effect of MDR-TB treatment
Adverse effects of MDR-TB treatment were associated with one or more of the following
factors.
1.3.2.1 Demographic Factors
Some demographic factors like being female is associated with increasing adverse effect of
the drugs.  According to retrospective cohort study conducted at Nepal show systematic
manifestation of adverse effect like hypothyroidism was seen among female patients accounts
75% of total patients followed and hepatitis was observed only in female patients but,
Arthralgia with hyperuricemia though more in male account 63.17 of patients (13).But a
retrospective cohort study conducted in Peru showed that there was no significant difference
between male and female (14).
Studies on adverse effect of MDR- TB treatment show that being older age increases the risk
of adverse effect of the drugs. A prospective study conducted in 2013 at Nepal show
adverse effect of MDR-TB treatment were more commonly observed among patients age
above 40 years they accounts around 94.1 % from those patients  developed adverse effect
of the MDR-TB treatment (13). According to a retrospective study done in Peru among 144
MDR-TB patients show that, there is an increasing incidence of MDR-TB drugs adverse
events as age increases (14). Overall, vulnerability to adverse reactions are more probable at
older ages especially at a hepatotoxic level due to a significant reduction in clearance rate of
metabolized drug agents by the cytochrome P450 enzyme, changes in the hepatic blood flow
distribution, as well as other factors affecting liver function (16),(17).
1.3.2.3 Co morbidity
Chronic illness increase risk of adverse effect of MDR-TB treatment. Diabetic patients with
MDR-TB are at risk for poor outcomes. The presence of diabetes mellitus may potentiate the
adverse effects of anti- tuberculosis drugs, like renal dysfunction and peripheral neuropathy.
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Patients with MDR-TB may have renal insufficiency at the time of MDR-TB diagnosis or they
may develop it later while on treatment secondary to use of injectable (4).
If patients have underling liver disease the risk of having adverse effect like hepatitis, will
increase since liver is one the commonest organs which can be affected by anti TB drugs.
Both first line and second line anti TB drugs can cause liver toxicity. On the other hand
patients with MDR-TB who need second line anti TB drugs may have an underling liver
disease. In both cases meticulous clinical and laboratory monitoring should be done to follow
up the progress (4), (18). Co-infection with hepatitis B or C has proven to be a high risk for
adverse drug effects (19), (20).
MDR-TB is often associated with higher mortality rates in the HIV-infected compared with the
non-infected. However, the use of ART in addition to treatment of DR-TB has been reported
to improve outcomes of MDR-TB in the HIV-infected (21, 22). Adverse effects are more
common in patients with HIV. The multiple medicines involved in MDR-TB with recognized
high toxicity risks, often combined with ART, results in a high incidence of adverse effects.
There are adverse effects common to both antituberculosis treatment and ART, which may
result in added rates of adverse events (18).
1.3.2.4 Nutritional status
Studies show that  nutritional status associated with increase the risk of adverse effect of
MDR-TB treatment patients with body mass index more than 25 kg/m2 (overweight and
obesity) was also associated with adverse reactions. Limited information is available
regarding this association, but a prior investigation reported that drug toxicity is high because
obese patients receive high dose of drugs according to total body weight (23).  Another study
reported that obesity can have some effects on drug metabolism which could increase
possibility of adverse events (24). But a retrospective study conducted in 2013 at Peru shows
that from a total of 70 patients around 40, 57.14% of patients are with BMI ≤ 18.5 kg/m2.
Majority of patients 82.5% develop adverse effect of MDR-TB from those patients around
64.7% develop GI symptoms (14).
1.3.2.5 Behavioral factors
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Smoking is reported to be associated with MDR- TB drug adverse reactions (25). A study
done in Peru show that statistically significant association between smoking and liver toxicity
due to Pyrazinamide, However, literature regarding this finding is limited and further studies
are needed (14).
Alcohol use can predispose and accelerate hepatotoxic effects caused especially by
isoniazid due to enzyme induction changes (26), (27). Cycloserine will have a higher
incidence of adverse effect in patients dependent on alcohol or other substances, including a
higher incidence of seizure (21).
The incidence of adverse effect of MDR-TB drugs increase with patients IV drugs users can
also be associated with hepatotoxicity. Overall, drugs have several effects which might affect
the liver's enzyme induction as well as predisposing to hepatitis infection especially among
intravenous drug users (19), (20).
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Fig 1: Conceptual framework for factors affecting MDR-TB treatment adverse effect.
Justification
Now a day’s the emergence MDR-TB is becoming a big challenge in the world because the
way of transmission and the HIV/AIDS pandemic hasten the prevalence of the case. The
challenge continue after the diagnosis because of the drugs of MDR-TB treatment was high
cost and second-line drugs have many more adverse effects than the first-line
Antituberculosis drugs (28).
The seriousness in severity and high in magnitude of side effect of second line drugs makes
the treatment of MDR-TB more complicated and that need good laboratory setup and experts.
So, more epidemiological data are necessary to assist policy makers and partners that going
to escalate the treatment initiating centers of MDR-TB.
There is no study on magnitude of common adverse effect of MDR-TB treatment and
associated factors this can cause the late detection of side effect that leads to poor out come
and death. Absence of this adverse effect contributes to missed adverse effect that can affect
the adherence of patient’s negatively. Therefore this study will be aimed at measuring the
magnitude of common adverse effect of MDR-TB Treatment and their associated factors,
enables health professional to stress on adverse effect of the treatment to have a better
outcome and policy makers and partners have big emphasis on MDR-TB treatment.
There is no evidence on associated factors of MDR- TB treatment adverse effect so, this
study will be aimed to determine magnitude and factors associated with adverse drug
reactions of MDR-TB treatment with special emphasis on MDR-TB medication, Co morbidity
(HIV/ADIS, diabetes, chronic liver disease, chronic renal disease etc..), nutritional status,
Behavioral factors (tobacco use, Alcohol use and other substance use) and socio
demographic factors.
Therefore this study also used to evaluate the MDR-TB program and serve as a base line
data for other researcher and for national MDR TB guide line.
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2. Objectives
2.1 General Objective
To assess the prevalence of adverse effect on MDR-TB treatment and associated factors at
St Peter TB Specialized Hospital and Gondar University Hospital, Ethiopia, 2014.
2.2 Specific objectives
 To measure the prevalence of adverse effect of MDR-TB treatment.
 To identify factors associated with adverse effects of MDR-TB treatment.
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3. Methods
3.1 Study design and period
Institution based retrospective cross sectional study was conducted from April 1 to 20, 2014.
3.2 Study Area
There are around 20 TICs in Ethiopia but only three of them are organized and treating
patients by second line drugs, the other sites now begin work by taking patients that start
treatment from other TICs and some of them are on enrolling patients.  These three senior
TICs are St Peters TB specialized hospital in Addis abeba, Gondar university hospital and
ALERT Hospital in Addis abeba. This study was conducted in two TICs St Peters TB
Specialized hospital in Addis abeba and Gondar university hospital because the data are
more organized.
St Peters TB specialized hospital is a general specialized Hospital under federal minster of
Health. There are 676 patients totally enrolled in MDR-TB treatment since the begging of the
St Peters Hospital is established as TIC.
Gondar University Hospital is the first referral hospital in North West Ethiopia expected to
serve more than 5 million people. There are 183 patients enrolled in MDR-TB treatment since
the establishment of GUH MDR-TB treatment initiating center.
3.3 Source and study population
The source population was all MDR-TB patients enrolled to MDR-TB treatment in the two
treatment initiating center Hospitals. The study populations were patients enrolled in MDR-TB
treatment and those took the drugs for more than 6 months.
3.3.1 Inclusion criteria
All patients those took MDR-TB treatment for more than 6 months.
3.3.2 Exclusion criteria
Those patients who have incomplete data files were excluded from the study.
3.3.3 Sample size Determination
Sample size was determined by using single population proportion formula by using the
following assumptions:
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In this study, sample size was determined using this formula
n = ( zα/2)2 p (1- p)
d2
Where
n = Sample size in
z1 = 1.96 for 95% confidence level
P= 32.8 % Proportion of MDR-TB treatment drug adverse effect (18)
d= 0.05
n = 339
Since the numbers of patients who are taking MDR-TB treatment and fulfilling the
inclusion criteria are 540, I have taken the entire patient to increase the power of the
studies.
3.3.4 Sampling procedure
Since the number of patients on MDR-TB treatment were small this study was include all
patients on MDR-TB treatment those fulfill the inclusion criteria.
3.4 Variables of the study
3.4.1 Dependent variable
MDR-TB treatment adverse effect (Presence/absence).
3.4.2 Independent variables
Socio demographic variables: Age, Sex, residence, marital status, Religion, educational
status, occupation and Wealth index.
Behavioral variables: alcohol consumption, Smoking, kchat chewing and other substance
abuse
Nutrition variable: BMI
Co morbidity: HIV/ADIS, Diabetes Mellitus, renal disorder, chronic liver disease, etc…..
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3.5 operational definitions
MDR-TB: defined as TB caused by Organisms that are resistant to isoniazid and rifampicin,
two first-line anti- TB drugs.
Adverse effect: - any unintended adverse response to a drug occurring at a therapeutic dose
and resulting in either death, drug withdrawal, change in the administration of the frequency or
dose of the drug or administration of other drug.
Hypokalemia: defined as when the serum potassium levels below 3.5meq/ml
Hypothyroidism: defined as when the serum thyroid hormone TSH level of > 4.25 mIU/L
Hyperuricemia: defined as when the serum uric acid level for female >5.6 mg/dl and for male
>7 mg/dl.
Elevated creatinine: defined as when the serum creatinine for female >0.9 mg/dl and for male
>1.2 mg/dl
Other chronic illness:-defined chronic illness other than HIV, Diabetes mellitus and chronic
liver disease.
3.6 Data collection
The patients’ files were assessed for the following data:
1. Socio demographic data of patients; Age, sex, occupation, residence, marital status,
religion, ethnicity, educational status and Wealth index.
2. Co-morbidities; diabetes, COPD, hypertension, chronic liver disease, CRF and others.
3. Side effects of anti-tuberculosis drugs
1 clinical AEs: - gastritis, Neurologic side effect, ototoxicity, Arthralgia, rash, hepatitis.
2. Laboratory AEs: - hypothyroidism, Hypokalemia, Elevated liver function tests (SGOT,
SGPT), Elevated creatinine level, Anemia
4. Nutritional status: BMI
5. Behavioral data: like alcohol consumption, smoking and any other substance abuse.
3.7 Data quality control
To assure the data quality high emphasis was given in designing data collection instrument.
Before starting the data collection, the organized check list was pre-tested on 20 patients in
st. Peter TB specialized hospital in Addis Ababa. Seven nurses and two health officers from
that hospital was selected. Training was given for the data collectors and supervisors.
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Throughout the course of the data collection frequent supervision was held on data collector
and regular meetings was held between the data collectors and the principal Investigator
together in which problematic issues arising on data collection.
The collected data was reviewed and checked for completeness before data entry;
The incomplete data was completed by contacting patients. Data entry format template was
produced and programmed.
3.8 Data management and analysis
Data was checked, coded and entered to Epi-info version 3.5.1 and was exported to SPSS
version 20 for analysis.
Data entry was made by the principal investigator. Binary logistic regression was fitted to
identify factors associated with common adverse effect of MDR-TB treatment. In descriptive
statistics tables, graphs mean and frequency was used to present the information.
Significance was obtained at Odds ratio with 95% CI and p< 0.05.
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4. Ethical consideration
Ethical clearance was obtained from Ethical review committee of university of
Gondar. Communication with St Peter TB Specialized Hospital and Gondar university hospital
was made in order to obtain permission letter.
Privacy and confidentiality of information taken from each chart was kept properly and
names or personal identifiers were not recorded.
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5. Dissemination of the result
The results of the study will be presented to University of Gondar, College of Medicine and
Health Sciences, Institute of Public Health as part of master of public health thesis and it will
also shared to Federal Ministry of Health, Amahara Regional Health Bureau, Gondar
University Hospital and other treatment initiating center that launch the treatment. Efforts will
be made to present the results on scientific conferences and peer reviewed journal
publications will be considered.
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6. Results
6.1 Socio- Demographic characteristics of the study participants
A total of 540 studies participants who had complete data were included. Among the total
59.8% were male and 40.2% female. The mean (SD) age of the patients were 30.89 (± 10.13)
years. About 33.3% of patients have attended secondary schooling. Patients from urban
were 71.3% and 46.5% of patients were married at the time of treatment. Majority of
respondents were had no fixed income 62.2% and patients unemployed to any work at the
time of treatment accounts 24.4%.
Table1. Socio-Demographic characteristics of MDR-TB patients at St Peters TB specialized
hospital and Gondar university hospital, 2014.
Socio-Demographic and
characteristics
frequency Percent (%)
Sex (n=540)
Male 323 59.8
Female 217 40.2
Age(year) (n=540)
<20 37 6.85
20-24 125 23.15
25-35 228 42.22
36-45 96 17.78
>45 54 10
Educational status
(n=540)
No formal education 103 19.1
Primary (1-8) 120 22.2
Secondary (8-12) 180 33.3
More than secondary 137 25.4
Residence (n=540)
Urban 385 71.3
rural 155 28.7
Marital status (n=540)
Never married 211 39.1
Currently married 251 46.5
Separated 69 13.8
Widowed 9 1.7
Occupation (n=540)
Government employee 69 12.8
Agricultural work 58 10.7
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Merchant 38 7
Student 95 17.6
Housewife 100 18.5
Unemployed 132 24.4
Others 48 8.9
Monthly income(in Birr)
(n=540)
<500 336 62.2
500-1000 97 18
1001-2000 99 18.3
>2000 8 1.5
6.1.1. Behavioral and chronic illness history distribution of MDR-TB patients
As regarding co morbidity; 21.5% respondents were co infected with HIV and 10.6%of
respondents were had history of cigarette smoking.
Table2. Behavioral and chronic illness history characteristics of MDR-TB patients at St Peters
TB specialized hospital and Gondar university hospital, 2014.
Behavioral and chronic
illness
Frequency Percent (%)
Hx. Of smoking (n=540)
Smoker 57 10.6
Non smoker 483 89.4
Hx. Of  Alcohol (n=540)
Yes 26 4.8
No 514 95.2
Hx. Chat chewing (n=540)
Yes 16 2.96
No 524 97.06
HIV status (n=540)
Positive 116 21.5
Negative 424 78.5
Hx. Of DM (n=540)
Yes 10 1.85
No 530 98.15
Hx. Other chronic illness
(n=540)
Yes 17 3.15
No 523 96.85
Hx. Other medication in
take (n=540)
Yes 122 22.6
No 418 77.4
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6.2 Prevalence of adverse effect
A total of 90% respondents were had at least one adverse effect while on treatment of MDR-
TB. Among the adverse effects severe gastritis 72.96% toke the leading followed by Arthralgia
(limit mobility) 40.74%.
Figure2. Magnitude of each common adverse effect of MDR-TB patients at st Peters TB
specialized hospital and Gondar university hospital, 2014.
6.2.1. Distribution of common adverse effect with socio demographic
characteristics of patients.
Among total patients male patients were had magnitude of adverse effect 59.1% and age
group 25-35 years were had magnitude of adverse effect 42.6%. According to this study from
all patients unemployed patients were had magnitude of adverse effect 23.9% and patients
with monthly income level <500 birr had magnitude of adverse effect 60.5%.
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Table3. Socio-Demographic characteristics wise distribution of adverse effect of MDR-TB
treatment at St Peters TB specialized hospital and Gondar university hospital, 2014.
Demographic and socio-economic
characteristics
frequency Percent (%)
Sex (n=486)
Female 199 40.9
male 287 59.1
Age (years) (n=486)
<20 27 5.5
20-24 107 22
25-35 207 42.6
36-45 92 18.9
>45 53 10.9
Educational status (n=486)
No formal education 94 19.3
Primary education 106 21.8
Secondary education 164 33.7
More than secondary 122 25.1
Residence (n=486)
Urban 347 71.4
Rural 139 28.6
Marital status (n=486)
Never married 183 37.7
Currently married 231 47.5
Separated 63 13
Widowed 9 1.9
Occupation (n=486)
Government employee 63 13.8
Agricultural work 54 11.1
Merchant 34 7
Student 70 16
House wife 94 19.3
Unemployed 116 23.9
Others 43 8.8
Monthly income level (n=486)
<500 294 60.5
500-1000 90 18.5
1000-2000 94 19.3
>2000 8 1.6
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6.2.3. Nutritional status of MDR-TB patients with distribution of adverse effect of MDR-
TB treatment.
According this study patient with malnutrition BMI less 16.5kg/m2 were had 44.4% of adverse
effects while on treatment of MDR-TB.
Table4. Nutritional status of patients with distribution of adverse effect of MDR-TB treatment
at St Peters TB specialized hospital and Gondar university hospital, 2014.
Nutritional status of patients on
MDR-TB treatment
frequency Percent (%)
BMI (n=486)
<16.5 216 44.4
16.5-18.49 167 33.3
18.5-24.99 103 22.2
6.2.4. Distribution of MDR-TB treatment adverse effects with behavioral, history of
chronic illness and history of any other medication in take than second line drugs.
Among total patients smokers 11.3% patients were developed any of the adverse effect while
on treatment. Among total patients those with history of drinking alcohol 5.1% were reported
they developed any of the adverse effects. From total patients HIV positive patients 22.8%
were reported at least one adverse effect while on treatment of MDR-TB.
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Table5. Behavioral, history of chronic illness and history other medication in take with
distribution of adverse effect of MDR-TB treatment at St Peters TB specialized hospital and
Gondar university hospital, 2014.
Behavioral, history chronic illness
and other medication in take
Frequency Percent (%)
Behavioral factors
Of patients (n=486)
Smoking history 55 11.3
Alcohol intake 25 5.1
Chat chewing
History of other chronic  illness
(n=486)
15 3.1
HIV positive 111 22.8
DM 9 1.9
History of OCI 17 3.5
History of other medication in take
(n=486)
Patients take other medication 117 24.1
6.3 Associated factors of adverse effect of MDR-TB treatment
Socio-demographic, nutritional status, behavioral and co-morbidity with history other medication
intake determinants in relation to presence of adverse effect were analyzed by bivariate and
multi-variate analyses using logistic regression models.
This study shows that there is no statistically significant association between adverse effect and
age group of patients. According to this study patients with BMI less than 16.5kg/m2 were had
2.8 times more likely odds of  developing  adverse effect than other patients [AOR: 2.83, 95%
CI: (1.57-5.08)].HIV positive patients had 2.3 times likely of developing adverse effect than other
patients [AOR: 2.34, 95% CI: (1.14-4.79)]. Table6: Shows the association some variables with
common adverse effects.
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Table6. Bivariate and multivariate analysis showing the association of selected independent
variables on common adverse effect of MDR-TB treatment at St Peters TB specialized hospital
and Gondar university hospital, 2014.
Variables
Adverse effect
Yes
(%)
No
(%)
COR(95%CI) AOR(95%CI)
Age (years)
<20 27 10 1
20-24 107 18 1.73(0.49-6.18)
25-35 207 21 3.18(0.90-11.19)
36-45 92 4 2.93(0.78-11.04)
>45 53 1 2.88(0.69-11.843)
BMI
<16.5 216 16 2.75(1.38-4.14) 2.83(1.57-5.08)*
16.5-18.49 167 17 1.88(1.08-3.29) 1.97(1.10-3.51)
18.5-24.99 103 21 1 1
HIV status
Positive 111 5 2.90(1.31-5.23) 2.34(1.14-4.79)**
Negative 375 49 1 1
Hx. Other
medication in take
Yes 117 5 3.10 (1.29-4.86)
No 369 49 1
Note: *p<0.05 ** P<0.01
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7. Discussion
The proportion of common adverse effects was 90% [95% CI: 85-94.9].
Regarding associated factors of common adverse effects, multivariate analysis of this
indicated that nutritional and HIV status were found to be significantly associated with
common adverse effects.
According to this study the proportion of common adverse effects were 90% this result was in
line with study conducted in Egypt which is 88% (15) but slight higher than study done in
Nepal 74.3% and 52% in Peru (13, 14) and this result was lower than study done in south
Africa which shows 98% (28) it might because of the socio-cultural characteristics of the
population and nutritional levels of the patients.
Among common adverse effects gastritis were reported higher which accounts 72.96% this
result was lower than study conducted in Egypt which was 88% it might be because due to
our poor documentation of patient chart (15) but, this result was higher than study done in
Nepal 21% and in Mumbai 45% it might because of difference in nutritional status of patients
studied (14, 12).
According to this study the proportion of Arthralgia was 40.74% which is contrast with study
conducted in Egypt 14.14% and Nepal 24.6% (15, 13) it might be due of the prevalence of
HIV co infection was high in this study relative to Egypt and Nepal that increase the risk of
Arthralgia, but this result was in consistence with study conducted in south Africa which was
40% (28).
Proportion of psychiatric disorder were 30.56% which was less than study conducted in south
Africa 46%(28) it might be because of high proportion of patients was HIV co infection in
south Africa but, this result was higher than study done in Egypt 16.1% it might be due to less
HIV co infected patients in Egypt however, this result was in line with study conducted in
Mumbai which 28%(15, 12).
This study shows that the proportion of Hypokalemia was 27.78% which higher than study
conducted in Egypt 23.3%, but this result was less than study done in South Africa which
shows 40% of patient’s report Hypokalemia this difference might be due to the prevalence of
HIV was high (15, 28).
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In this study the prevalence of peripheral neuropathy were 17.96 % which in contrast with
study conducted in Mumbai 37% and South Africa 74% respectively this difference might be
because the above two study were conducted among HIV co infected patients (12, 28).
This study shows that there is no statistically significant association between adverse effect
and age group of patients. However study done in Peru and Nepal show that age of the
patients had significant association with presence of adverse effect (13, 14) whereas, age of
the patients had not significant association with adverse effects study conducted in Egypt
(15).
This finding revealed that, as the body mass index of patients decrease the risk of developing
adverse effect increase. Patients with BMI < 16.5kg/m2 were 2.83 times [AOR: 2.83, 95% CI:
(1.57-5.08)] more likely to develop adverse effect. The finding of this was consistent with
study conducted in Nepal and Peru (13, 14) respectively. This might due to poor nutritional
status. Evident show that when patients had malnutrition especially PEM it associated with
decrease the mucosal layer of the gastric that predispose patients to develop gastritis (24).
HIV infected patients had 2.3 times higher odds of developing adverse effect than HIV
negative patients [AOR: 2.34, 95% CI:(1.14-4.79)] this result was in line with study done in
south Africa and Mumbai(12, 28).
This finding might be due to HIV infected patients other medication than the anti TB drugs,
among the medications ART was the main so patients on ART treatments some of this ART
drugs like efanvirenz increase the risk of psychosis with the cycloserine and some drugs like
stavudin increase the risk of developing peripheral neuropathy and HIV positive patients had
more psychosocial problems and HIV by itself increase adverse effect like peripheral
neuropathy (28).
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8. Conclusion
The proportion of common adverse effect on MDR-TB treatment was high. Among the
adverse effects the most common was severe gastritis followed by Arthralgia. Malnutrition and
HIV co infection were significantly associated with the presence of MDR-TB treatment
adverse effect.
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9. Recommendation
Considering nutritional package for MDR-TB patients and fulfilling the laboratory setups while
opening TICs to easily diagnose patients those develop adverse effect before they come up
with unfavorable outcome was expected from Policy makers and program designer to get
better outcome of MDR-TB treatment.
Especial emphasis for malnourished patients, HIV co infected patients and patients took other
medication while on treatment of MDR-TB by TICs will improve the outcome of the MDR-TB
treatment.
Patients on MDR-TB treatment should have to correct there nutritional habit to came up with
better outcome of their treatment.
Researcher better if they study more on the specific adverse effect and its associated factors
for each adverse effect with prospective cohort study design.
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10. Annex
Check list on magnitude of MDR-TB treatment adverse effect and its associated
factors in selected TICs in Ethiopia, 2014
Identification
Code (card number, serial number)
Part – I Socio- demographic information
Question Response
1. Sex 1. Male
2. female
2. Age Years----------------
3. Educational Status 1.No formal education
2.Primary
3.Secondary
4. More than secondary
4. Residence 1.Urban
2.Rural
5. Marital status at time of treatment 1.Never married
2.Currently married
3.separated
4.Divorced
5.Widowed
6. Which of the following describes your
main work status?
1.Health professional
2.Government Employee
3.Agricultural Work
4.Merchant
5.Spiritual Work
6.Soldier
7.Student
8.Housewife
9.Retired
10.Unemployed /unable to work/
11.Unemployed /able to work/
12.Other
7 Monthly wealth index in terms of money ------------------- birr/month
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Part II Anthropometric Measurement
8 Weight In Kg-----------------
9 Height In meter-------------------
10 BMI /body mass index Kg/m2
Part III Life style (Behavioral) information
Question Response
11 Did the patient smoke cigarette? 1.Yes
2.No
12 If yes for how long have you the patient
smoke?
-----------------(Y) months
13 On average how many cigarettes/day did
the patient use?
-----------------------
14 Did the patient drink alcohol products
regularly?
1.Yes
2.No
15 If yes, What kind of Alcohol? 1.Tell
2. Beer
3.Areki
4.Other Specify ----------
16 On average how many bottles? ---------------------------------/day(week)
17 If yes, for question 15 how long have
consumed alcohol?
----------------(Y) months
18 Did the patient have history of Chat
Chewing?
1.yes
2.No
19 Did the patient have history of other
substance use?
1.yes
2.No
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20 If yes, please specify -----------------
Part IV Co morbidities information
Question Response
21. HIV status of the patient at time
treatment?
1.posetive
2.Negative
22. If positive, what is CD4 count at time of
initiation of treatment?
1.<50
2.50-100
3.100-200
4.200-350
5..350
23. Is the patient on ART treatment? 1.Yes
2.No
24. If yes, how long have you been on ART ----------months/years
25. Does the patient have history of
Diabetes Mellitus?
1.Yes
2.No
26. Does the patient have history of Chronic
Liver Disease?
1.Yes
2.No
27. Does the patient have any other chronic
illness?
1.yes
2.no
28. If yes, please specify ----------------
29. Does the patient taking other
medications at the time of treatment on
MDR-TB ?
1. Yes
2. No
30. If yes please specify -----------------------
Part V History of treatment and Adverse effect Information
Question Answer
31. Doe the patient have any treatment
adverse effect?
1.yes
2. no
32. If yes, which clinical Adverse effect
does the patient develop?
Clinical Adverse effect
1. Gastritis
2. Arthralgia
3. Ototoxicity
4. Peripheral neuropathy
5. Psychiatric manifestation
( depression, anxiety, psychosis,
suicidal ideation)
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6. Seizure
7. Rash
8. Headache
9. Sleeping disturbance
10. Other------------------------------
33. If there were any adverse effect at
what month of treatment the patients
develop the Adverse effect?
---------------------months
34. What was the outcome of the patient
with regard to the adverse effect?
1. Ancillary medication given
2. Drug dose decreased
3. The suspected Drug  holding
4. Totally all drug holding
5. Suspected drug changed
6. Died
7. Defaulted
For laboratory detected adverse effects
35. Doe the patient have any treatment
adverse effect?
1.yes
2.no
36. If yes, which laboratory
Adverse effect the patients
develop?
Answer
Lab. Test
result
Month of Rx. The patient
develop adverse effect
1. Elevated Liver function test
(ALT)
Normal range SGOT(0-31 u/l)
SGPT (0-32u/l)
1.yes
2. no
2. Hypothyroidism
Normal range TSH (0.34-4.25 µ
IU/ml)
1.yes
2.no
3. Hyper Uric acid level
Normal range U/A
Female (2.5-5.6 mg/dl)
Male     (3.1-7.0 mg/dl)
1.yes
2.no
4. Hypokalemia
Normal range of K(3.5-5.0meq/l)
1.yes
2. no
5. Hyperkalemia
Normal range of K(3.5-5.0meq/l)
1.yes
2.no
6. Elevated Creatinine(cr)
Normal range of Creatinine
Female (0.5-0.9 mg/dl)
Male      (0.6-1.2 mg/dl)
1.yes
2.no
7. Anemia
Normal range of hemoglobin
1.yes
2.no
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Female (12.0-15.8 g/dl)
Male     (13.3-16.2 g/dl)
37. What was the outcome of the patient
with regard to the adverse effect?
1. Ancillary medication given
2. Drug dose decreased
3. The suspected Drug  holding
4. Totally all drug holding
5. Suspected drug changed
6. Died
7. Defaulted
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